

Certificate of Analysis for NR-51569

Pseudomonas aeruginosa, Strain MRSN 11538

Catalog No. NR-51569

This reagent is the tangible property of the U.S. Government.

Product Description:

Pseudomonas aeruginosa (P. aeruginosa), strain MRSN 11538 was isolated in 2012 from a human wound as part of a surveillance program in the United States. P. aeruginosa, strain MRSN 11538 was deposited as sensitive to amikacin, aztreonam, ciprofloxacin, cefepime, gentamicin, levofloxacin, piperacillin/tazobactam and tobramycin, intermediately resistant to ceftazidime and resistant to imipenem and meropenem.

Lot: 70025029¹ Manufacturing Date: 05JUN2019

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis		
Cellular morphology	Gram-negative rods	Gram-negative rods
Colony morphology ²	Report results	Circular, low convex, undulate,
		opaque and green (Figure 1)
Motility (wet mount)	Report results	Motile
VITEK® 2 (GN card)	P. aeruginosa (≥ 89%)	P. aeruginosa (98%)
Antibiotic Susceptibility Profile ³		
VITEK® (AST-GN81 Card)		
Ampicillin	Report results	Resistant (≥ 32 µg/mL)
Amoxicillin/clavulanic acid	Report results	Resistant (≥ 32 µg/mL)
Piperacillin/tazobactam	Sensitive	Intermediate (64 µg/mL) ⁴
Cefazolin	Report results	Resistant (≥ 64 µg/mL)
Cefoxitin	Report results	Resistant (≥ 64 µg/mL)
Ceftazidime	Intermediate	Intermediate (16 µg/mL)
Ceftriaxone	Report results	Resistant (≥ 64 µg/mL)
Cefepime	Sensitive	Intermediate (16 µg/mL) ⁵
Meropenem	Resistant	Resistant (≥ 16 µg/mL)
Amikacin	Sensitive	Sensitive (≤ 2 µg/mL)
Gentamicin	Sensitive	Sensitive (≤ 1 µg/mL)
Tobramycin	Sensitive	Sensitive (≤ 1 µg/mL)
Ciprofloxacin	Sensitive	Sensitive (1 µg/mL)
Levofloxacin	Sensitive	Intermediate (4 µg/mL) ⁶
Tetracycline	Report results	Resistant (≥ 16 µg/mL)
Nitrofurantoin	Report results	Resistant (≥ 512 µg/mL)
Trimethoprim/sulfamethoxazole	Report results	≥ 320 µg/mL ⁷
Genotypic Analysis	·	
Sequencing of 16S ribosomal RNA gene	≥ 99% sequence identity to	99.9% sequence identity to
(~ 1470 base pairs)	P. aeruginosa, strain MRSN 11538	P. aeruginosa, strain MRSN 11538
	(GenBank: RXWN01000143.1)	(GenBank: RXWN01000143.1)
Purity (post-freeze) ⁸	Growth consistent with expected	Growth consistent with expected
	colony morphology	colony morphology
Viability (post-freeze) ²	Growth	Growth

¹NR-51569 was produced by inoculation of the depositor material into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar kolles, which were grown for 1 day at 37°C in an aerobic atmosphere to produce this lot.

BEI Resources

www.beiresources.org

E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898

²1 day at 37°C in an aerobic atmosphere on Tryptic Soy agar

³Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018)

⁴P. aeruginosa, strain MRSN 11538 was deposited as sensitive to piperacillin/tazobactam. Répeated antibiotic susceptibility testing determined that strain MRSN 11538 is intermediately resistant to piperacillin/tazobactam.

⁵P. aeruginosa, strain MRSN 11538 was deposited as sensitive to cefepime. Repeated antibiotic susceptibility testing determined that strain MRSN 11538 is intermediately resistant to cefepime.



SUPPORTING INFECTIOUS DISEASE RESEARCH

Certificate of Analysis for NR-51569

⁶P. aeruginosa, strain MRSN 11538 was deposited as sensitive to levofloxacin. Repeated antibiotic susceptibility testing determined that strain MRSN 11538 is intermediately resistant to levofloxacin.

Figure 1: Colony Morphology



/Heather Couch/ **Heather Couch**

09 DEC 2019

Program Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898

⁷Trimethoprim/sulfamethoxazole MIC interpretive standards are not available for *P. aeruginosa*, however most clinical isolates are resistant to trimethoprim/sulfamethoxazole. For more information, please refer to Köhler, T., et al. "Multidrug Efflux in Intrinsic Resistance to Trimethoprim and Sulfamethoxazole in *Pseudomonas aeruginosa*." <u>Antimicrob. Agents Chemother.</u> 40 (1996): 2288-2290. PubMed: 9036831.

⁸Purity of this lot was assessed for 7 days at 37°C in an aerobic atmosphere with and without 5% CO₂ on Tryptic Soy agar.